Development

Christa Myers is a process chemical engineer for CRB.

Articles

A new focus on speed to market creates challenges for facility design and construction.

The Need for Speed: How Operation Warp Speed Shifted the Pharma Industry

Genezen has opened its new process development and analytical lab for viral vector production.

Genezen Starts Up Operations at Lenti- and Retroviral Vector Process Development Lab

Sterling Pharma Solutions has announced a £10 million (US$13.5 million) investment into process development and manufacturing capacity at its site in Dudley, UK.

Sterling Pharma Solutions Invests in Process Development and Manufacturing in Dudley, UK

Ajinomoto and its subsidiary company, Ajinomoto Genexine, have partnered with Insilico Biotechnology to accelerate and improve process development and production of biologics using digital twin technology.



Partnership Aims to Accelerate and Improve Smart Bioprocess Development Solutions

 is an AFI member and participates in the AFI process validation working group.

Alessandro Regola is the AFI vice president in Milan and coordinator of the AFI Quality Section, and serves as pharmaceutical consultant in quality systems.

Knowledge management has gained increasing importance in the pharmaceutical industry over the past 10–15 years

Pharmaceutical Knowledge Management: Experiences in Drug Development and Manufacturing

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.

Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs

Meg Rivers is the former senior editor for 

Alternatives to animal testing and in-vivo assays are occurring as a result of recent scientific advances.

In Vivo Falls Behind In Vitro for Adventitious Agent Testing

According to Charles River Laboratories, when asked how long it takes for a drug to be developed and approved for market in the United States, only 10% of 1,500 Americans polled correctly estimated that it takes between 10 and 15 years.

Only 10% of Americans Understand the Drug Development Timeline, Survey Finds

In an amendment to their existing contract manufacturing agreement, Celsian and Poly Pharm expand GEN-1 program collaboration to add clinical and commercial batches of investigational vaccine.

Celsion and Poly Pharm to Manufacture Celsion’s DNA-Based Vaccine

Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.